On the prevention of haematogenous tumor metastases in rats the role of the proteinase inhibitor ?Trasylol?

1980 ◽  
Vol 97 (2) ◽  
pp. 129-135 ◽  
Author(s):  
R. Stein-Werblowsky
Keyword(s):  
Proteinase Inhibitor ◽  
Tumor Metastases

scholarly journals Alpha-1 Antitrypsin Deficiency: Principles of Care

2020 ◽  
Vol 33 (6) ◽  
pp. 433
Author(s):  
Joana F. Rodrigues ◽  
Alexandra Mineiro ◽  
António Reis ◽  
David G. Ventura ◽  
Fernando Fernandez-Llimos ◽  
...  
Keyword(s):  
Proteinase Inhibitor ◽  
Clinical Care ◽  
High Standard ◽  
Access To Treatment ◽  
Presenting Symptoms ◽  
Patient Organizations ◽  
Antitrypsin Deficiency ◽  
Alpha 1 Antitrypsin Deficiency ◽  
Alpha 1 Antitrypsin

Alpha-1 antitrypsin deficiency is an autosomal co-dominant inherited disorder that results in decreased circulating levels of alpha-1 antitrypsin (also known as alpha-1 proteinase inhibitor) and predisposes affected individuals to early onset lung and liver disease. There is currently no cure for alpha-1 antitrypsin deficiency. However, appropriate treatment and a high standard of clinical care can prevent patients from being seriously affected and having to undergo major medical interventions, such as organ transplantation. Beyond managing the symptoms associated with alpha-1 antitrypsin deficiency, alpha-1 proteinase inhibitor therapy is the only treatment for the condition’s underlying cause. Early diagnosis is important to ensure efficient therapeutic strategies and to minimize further deterioration of lung function. alpha-1 antitrypsin deficiency is under diagnosed globally, partly because the disease has no unique presenting symptoms. This document was prepared by a Portuguese multidisciplinary group and it aims to set out comprehensive principles of care for Alpha-1 antitrypsin deficiency. These include the importance of registries, the need for clinical research, the need for consistent recommendations (regarding diagnosis, treatment and monitoring), the role of reference centres, the requirement for sustained access to treatment, diagnostic and support services, and the role of patient organizations.

Abstract C57: The role of stromal cells in tumor metastases

2009 ◽  
Author(s):  
Annique Duyverman ◽  
Dan G. Duda ◽  
Ernst J.A. Steller ◽  
Dai Fukumura ◽  
Rakesh K. Jain
Keyword(s):  
Stromal Cells ◽  
Tumor Metastases

scholarly journals The role of endothelium in factor Xa regulation: the effect of plasma proteinase inhibitors and hirudin

Blood ◽  
1988 ◽  
Vol 71 (5) ◽  
pp. 1321-1328 ◽  
Author(s):  
RC Friedberg ◽  
PO Hagen ◽  
SV Pizzo
Keyword(s):  
Active Site ◽  
Proteinase Inhibitor ◽  
Human Factor ◽  
Antithrombin Iii ◽  
Proteinase Inhibitors ◽  
Factor Xa ◽  
Proteolytic Degradation ◽  
Chromogenic Substrates ◽  
And Function

Abstract The role of endothelium in the inhibition of human factor Xa was studied in a plasma environment. Human factor Xa can bind to and function on bovine aortic endothelium in a manner similar to that of bovine factor Xa. Approximately 70% of the bound factor Xa is subject to inhibition by plasma proteinase inhibitors, and the remaining 30% is irreversibly bound as part of a 125 Kd membrane-associated complex not subject to proteolytic degradation. The proportion reversibly bound and its rate of release do not alter with changes in calcium, citrate, heparin, or active proteinase inhibitor concentrations. The principal plasma proteinase inhibitor of human factor Xa was antithrombin III, which accounted for 60% to 65% of factor Xa released from endothelium, with alpha 1-proteinase inhibitor inactivating 20% to 25% and alpha 2- macroglobulin approximately 15%. All of the reversibly bound factor Xa was identified in complex with one of these three proteinase inhibitors. The thrombin active-site inhibitor hirudin was found to markedly accelerate the displacement of reversibly bound factor Xa from the endothelium and to associate specifically with factor Xa without a loss of activity toward chromogenic substrates, perhaps accounting for a novel mechanism of anticoagulation.

scholarly journals The role of plasma serine leukocyte proteinase inhibitor in the body's defense against COVID-19

2021 ◽  
Vol 98 (5) ◽  
pp. 567-578
Author(s):  
A. L. Kravtsov ◽  
S. A. Bugorkova
Keyword(s):  
Blood Plasma ◽  
Proteinase Inhibitor ◽  
Global Economy ◽  
Neutrophil Extracellular Traps ◽  
The Body ◽  
Human Blood Plasma ◽  
Leukocyte Elastase ◽  
Extracellular Traps ◽  
Coronavirus Infection

The COVID-19 pandemic continues, causing colossal damage to the population and the global economy. As COVID-19 is studied, new data are emerging regarding the risk of severe coronavirus infection in patients with α1-antitrypsin deficiency. α1 -Antitrypsin is the main inhibitor and key endogenous regulator of the serine leukocyte proteinase activitry released from the granules of activated neutrophils to the cell surface and into the extracellular space. It has been established that the number of cases of severe course and death of COVID-19 in the territories of 68 countries of the world correlates with the frequency of the spread of mutations in the proteinase inhibitor gene among the population of these countries, at which the concentration of α1-antitrypsin in the human blood plasma is 10 times lower than normal. All this contributes to the revision of a number of provisions of the pathogenesis and therapy of a new coronavirus infection.The review presents an analysis of the literature on the role of an inhibitor of serine leukocyte proteinases in protecting the body from COVID-19. The participation of α1-antitrypsin in the inhibition of SARS-CoV-2 penetration into the respiratory tract epithelial cells, in the protection of the vascular endothelium, blood plasma proteins and elastin of the lung tissue from the damaging effect of leukocyte elastase released during neutrophil degranulation and the formation of neutrophil extracellular traps (NETs) is considered. The role of a1-antitrypsin in suppressing inflammation by limiting the secretion of proinflammatory cytokines and neutrophil extracellular traps into the blood has been shown. The individual links in the pathogenesis of the new coronavirus infection have been detailed, which will allow revising the strategy for reducing the risks of severe course of COVID-19.

The Role of Stromal Cells in Tumor Metastases.

2009 ◽  
Author(s):  
A. Pieters ◽  
D. Duda ◽  
E. Steller ◽  
D. Fukumura ◽  
R. Jain
Keyword(s):  
Stromal Cells ◽  
Tumor Metastases
Sign in / Sign up

Export Citation Format

Share Document